Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy
Molecular Cancer2024Vol. 23(1), pp. 123–123
Citations Over TimeTop 10% of 2024 papers
Marc Zuckermann, Chen He, Jared Andrews, Aditi Bagchi, Roketa Sloan-Henry, Brandon Bianski, Xie Jia, Yingzhe Wang, Nathaniel Twarog, Arzu Onar‐Thomas, Kati Ernst, Lei Yang, Yong Li, Xiaoyan Zhu, Jennifer K. Ocasio, Kaitlin M. Budd, James Dalton, Xiaoyu Li, Divyabharathi Chepyala, Junyuan Zhang, Ke Xu, Laura D. Hover, Jordan T. Roach, Kenneth Chun‐Ho Chan, Nina Hofmann, Peter J. McKinnon, Stefan M. Pfister, Anang A. Shelat, Zoran Ranković, Burgess B. Freeman, Jason Chiang, David Jones, Christopher L. Tinkle, Stuart N. Baker
Abstract
We comprehensively investigated the combination of MET inhibition and radiotherapy as a novel treatment option for MET-driven pHGG. Our seminal preclinical data package includes pharmacokinetic characterization, recapitulation of clinical outcomes, coinciding results from multiple complementing in vivo studies, and insights into molecular mechanism underlying increased efficacy. Taken together, we demonstrate the groundbreaking efficacy of capmatinib and radiation as a highly promising concept for future clinical trials.
Related Papers
- → LncRNA LINC01094 contributes to glioma progression by modulating miR-224-5p/CHSY1 axis(2021)19 cited
- → MiRNA-93 functions as an oncogene in glioma by directly targeting RBL2.(2018)25 cited
- → Melanoma-associated antigen A2 is overexpressed in glioma and associated with poor prognosis in glioma patients(2018)7 cited
- → A dynamical model of combination therapy applied to glioma(2022)2 cited
- → CPLX2 is a novel tumor suppressor and improves the prognosis in glioma(2023)